Agios Q1 2023: PYRUKYND revenue $5.6M, net loss improves to $81M, cash $1.0B

AGIOS PHARMACEUTICALS, INC.

2023-Q1 EPS reported -$1.47 revenue$5,609,000

PYRUKYND net revenue of $5.6M in Q1 2023; 127 unique patients enrolled, 89 on therapy.
Net loss of $81.0M improved from $94.8M in Q1 2022; R&D expense $67.3M, SG&A $28.4M.
Cash, cash equivalents and marketable securities $1.0B as of March 31, 2023.
Phase 2 sickle cell data (RISE UP) expected mid-2023; ENERGIZE/ENERGIZE-T enrollment closed.
Appointed Jeffrey Capello to board; Paul Clancy stepping down effective June 13, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $5.6 million, net income $81.0 million.

Period: the first quarter ended March 31, 2023
Revenue: $5.6 million
Net income: $81.0 million
Result: reported results

Exact text from the filing

Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 • U.S. PYRUKYND ® Net Revenue of $5.6 Million in Q1; $1.0 Billion of Cash, Cash Equivalents and Marketable Securities as of March 31, 2023 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.